References
- Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am J Med 2006;119(7 Suppl 1):S30-5
- Liamis G, Rodenburg EM, Hofman A, et al. Electrolyte disorders in community subjects: prevalence and risk factors. Am J Med 2013;126(3):256-63
- Filippatos TD, Elisaf MS. Hyponatremia in patients with heart failure. World J Cardiol 2013;5(9):317-28
- Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000;342(21):1581-9
- Karp BI, Laureno R. Pontine and extrapontine myelinolysis: a neurologic disorder following rapid correction of hyponatremia. Medicine (Baltimore) 1993;72(6):359-73
- Kumar S, Fowler M, Gonzalez-Toledo E, Jaffe SL. Central pontine myelinolysis, an update. Neurol Res 2006;28(3):360-6
- Graff-Radford J, Fugate JE, Kaufmann TJ, et al. Clinical and radiologic correlations of central pontine myelinolysis syndrome. Mayo Clin Proc 2011;86(11):1063-7
- Hart BL, Eaton RP. Osmotic Myelinolysis. N Engl J Med 1995;333(19):1259
- Lauriat SM, Berl T. The hyponatremic patient: practical focus on therapy. J Am Soc Nephrol 1997;8(10):1599-607
- Borroni G, Maggi A, Sangiovanni A, et al. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig Liver Dis 2000;32(7):605-10
- Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122(9):857-65
- Renneboog B, Musch W, Vandemergel X, et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. Am J Med 2006;119(1):71. e1-8
- Shea AM, Hammill BG, Curtis LH, et al. Medical costs of abnormal serum sodium levels. J Am Soc Nephrol 2008;19(4):764-70
- Milionis HJ, Liamis GL, Elisaf MS. The hyponatremic patient: a systematic approach to laboratory diagnosis. CMAJ 2002;166(8):1056-62
- Liamis G, Milionis HJ, Elisaf M. Endocrine disorders: causes of hyponatremia not to neglect. Ann Med 2011;43(3):179-87
- Sterns RH, Silver SM. Cerebral salt wasting versus SIADH: what difference? J Am Soc Nephrol 2008;19(2):194-6
- Liamis G, Christidis D, Alexandridis G, et al. Uric acid homeostasis in the evaluation of diuretic-induced hyponatremia. J Investig Med 2007;55(1):36-44
- Smith D, Moore K, Tormey W, et al. Downward resetting of the osmotic threshold for thirst in patients with SIADH. Am J Physiol Endocrinol Metab 2004;287(5):E1019-23
- Chow KM, Szeto CC, Wong TY, et al. Risk factors for thiazide-induced hyponatraemia. QJM 2003;96(12):911-17
- Decaux G. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by long loop diuretics. Nephron 1983;35(2):82-8
- Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann Intern Med 1984;100(6):777-82
- Elisaf M, Theodorou J, Pappas C, Siamopoulos K. Successful treatment of hyponatremia with angiotensin-converting enzyme inhibitors in patients with congestive heart failure. Cardiology 1995;86(6):477-80
- Greenberg A. Diuretic complications. Am J Med Sci 2000;319(1):10-24
- Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001;110(7):582-4
- Liamis G, Milionis HJ, Elisaf M. A review of drug-induced hypernatraemia. NDT Plus 2009;2(5):339-46
- Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998;449251-76
- Nakamura Y, Haneda T, Osaki J, et al. Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000;391(1-2):39-48
- Fukuzawa J, Haneda T, Kikuchi K. Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor. Mol Cell Biochem 1999;195(1-2):93-8
- Howl J, Ismail T, Strain AJ, et al. Characterization of the human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function. Biochem J 1991;276(Pt 1):189-95
- Tanoue A, Ito S, Honda K, et al. The vasopressin V1b receptor critically regulates hypothalamic-pituitary-adrenal axis activity under both stress and resting conditions. J Clin Invest 2004;113(2):302-9
- Xu DL, Martin PY, Ohara M, et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 1997;99(7):1500-5
- Kwon TH, Hager H, Nejsum LN, et al. Physiology and pathophysiology of renal aquaporins. Semin Nephrol 2001;21(3):231-8
- Fushimi K, Uchida S, Hara Y, et al. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993;361(6412):549-52
- Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int 2006;69(12):2124-30
- Ghali JK, Farah JO, Daifallah S, et al. Conivaptan and its role in the treatment of hyponatremia. Drug Des Devel Ther 2009;3253-68
- Tolvaptan monograph. Available from: http://samsca.ca/assets/doc/monograph_en.pdf [Last accessed 9 February 2014]
- FDA drug safety communication - FDA Limits duration and usage due to possible liver injury leading to organ transplant or death. Available from: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm350185.htm [Last accessed 12 February 2014]
- Li-Ng M, Verbalis JG. Conivaptan: Evidence supporting its therapeutic use in hyponatremia. Core Evid 2010;483-92
- Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-112
- Verbalis JG, Goldsmith SR, Greenberg A, et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-21
- Albright JD, Reich MF, Delos Santos EG, et al. 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998;41(14):2442-4
- Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002;36(5):1197-205
- Lixivaptan. FDA Briefing Document for the Cardiovascular and Renal Drugs advisory (CRDAC). Available from: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm318867.pdf. [Last accessed 8 February 2014]
- Martin PY, Abraham WT, Lieming X, et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999;10(10):2165-70
- Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001;138(1):18-21
- Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003;37(1):182-91
- Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124(4):933-9
- Ghali JK, Orlandi C, Abraham WT; Investigators C-LS. The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study. Eur J Heart Fail 2012;14(6):642-51
- Abraham WT, Hensen J, Gross PA, et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney Int 2012;82(11):1223-30
- Abraham WT, Decaux G, Josiassen RC, et al. Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int 2012;82(11):1215-22
- Abraham WT, Aranda JM, Boehmer JP, et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clin Transl Sci 2010;3(5):249-53
- Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol 2012;73(4):579-87
- Siegel AJ. Hyponatremia in psychiatric patients: update on evaluation and management. Harv Rev Psychiatry 2008;16(1):13-24
- Josiassen RC, Goldman M, Jessani M, et al. Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia. Biol Psychiatry 2008;64(12):1097-100
- Josiassen RC, Curtis J, Filmyer DM, et al. Tolvaptan: a new tool for the effective treatment of hyponatremia in psychotic disorders. Expert Opin Pharmacother 2010;11(4):637-48
- FDA. Cardiovascular and Renal Drugs Advisory Committee meeting announcement. Available from: www.fda.gov/AdvisoryCommittees/Calendar/ucm313273.htm [Last accessed 14 February 2014]
- FDA Panel Rejects Lixivaptan for CHF. Available from: www.medpagetoday.com/Washington-Watch/FDAGeneral/34753 [Last accessed 24 March 2014]
- FDA panel votes against Cornerstone’s lixivaptan. Available from: www.pharmatimes.com/article/12-09-14/FDA_panel_votes_against_Cornerstone_s_lixivaptan.aspx [Last accessed 24 March 2014]